探讨罗氏肾病Ⅲ号方（由海藻、黄芪、丹参、熟地黄、煅牡蛎、鱼腥草、荆芥穗等组成）联合常规西药治疗脾 肾亏虚、浊毒瘀阻型3-5期非透析慢性肾脏病（chronic kidney disease，CKD）的临床效果。【方法】将180例脾肾亏虚、浊毒瘀 阻型3-5期非透析CKD患者随机分为观察组和对照组，每组各90例。对照组给予常规西医对症治疗，观察组在对照组的基 础上联合罗氏肾病Ⅲ号方治疗，疗程均为1个月。观察2组患者治疗前后血清炎症因子水平及肾功能指标、尿蛋白指标的变 化情况，并评价2组患者的临床疗效和安全性。【结果】（1）治疗1个月后，观察组的总有效率为95.56%（86/90），对照组为 81.11%（73/90），组间比较（χ2检验），观察组的疗效明显优于对照组（P＜0.01）。（2）治疗后，2组患者的血清转化生长因子β1 （TGF-β1）、单核细胞趋化蛋白1（MCP-1）、肿瘤坏死因子α（TNF-α）水平均较治疗前明显降低（P＜0.05），且观察组的降低 幅度均明显优于对照组（P＜0.01）。（3）治疗后，2组患者的血尿素氮（BUN）、血清肌酐（Scr）、血尿酸（UA）、胱抑素C（Cys-C） 水平均较治疗前明显降低（P＜0.05），且观察组的降低幅度均明显优于对照组（P＜0.01）。（4）治疗后，2组患者的24 h尿蛋白 定量和尿微量白蛋白水平均较治疗前明显降低（P＜0.05），且观察组的降低幅度均明显优于对照组（P＜0.01）。（5）观察组的不 良反应发生率为4.44%（4/90），明显低于对照组的15.56%（14/90），组间比较，差异有统计学意义（P＜0.05）。【结论】罗氏肾 病Ⅲ号方联合常规西药治疗脾肾亏虚、浊毒瘀阻型3-5期非透析CKD患者的临床效果较好，可显著缓解患者机体炎性反 应，改善患者的肾功能，降低患者的尿蛋白排出量，且用药的安全性更高。

To investigate the clinical effect of LUO’s Nephropathy Recipe Ⅲ（composed of Sargassum， Astragali Radix， Salviae Miltiorrhizae Radix et Rhizoma， Rehmanniae Radix Praeparata， calcined Ostreae Concha， Houttuyniae Herba， Schizonepetae Spica， etc.） combined with conventional western medicine in treating stage 3-5 non-dialysis chronic kidney disease（CKD）of spleen-kidney deficiency with turbidity-toxinstasis obstruction type. Methods A total of 180 patients with stage 3- 5 non- dialysis CKD of spleen- kidney deficiency with turbidity-toxin-stasis obstruction type were randomly divided into observation group and control group，with 90 cases in each group. The control group was given conventional western medicine for symptomatic treatment，and the observation group was treated with LUO’s Nephropathy Recipe Ⅲ on the basis of treatment for the control group. The course of treatment for the two groups covered one month. Before and after treatment，the levels of serum inflammatory factors，renal function indicators and urine protein parameters in the two groups were observed. After treatment，the clinical efficacy and safety of the two groups were evaluated. Results（1）After one month of treatment，the total effective rate in the observation group was 95.56%（86/90）and that in the control group was 81.11%（73/90）. The intergroup comparison（tested by chi-square test）showed that the efficacy of the observation group was significantly superior to that of the control group（P＜0.01）.（2）After treatment，the serum levelsofinflammatoryfactorsoftransforminggrowthfactor β1（TGF-β1），monocytechemotacticprotein 1（MCP-1）， and tumor necrosis factor α（TNF-α）in the two groups were significantly decreased compared with those before treatment（P＜0.05），and the decrease in the observation group was significantly superior to that in the control group（P＜0.01）.（3）After treatment， the levels of renal function indicators of blood urea nitrogen（BUN）， serum creatinine（Scr）， blood uric acid（UA）， and cystatin C（Cys-C）in the two groups were significantly decreased compared with those before treatment（P＜0.05）， and the decrease in the observation group was significantly superior to that in the control group（P＜0.01）.（4）After treatment， the levels of 24-hour urine protein quantification and urine microalbumin in the two groups were significantly decreased compared with those before treatment（P＜0.05）， and the decrease in the observation group was significantly superior to that in the control group（P＜0.01）.（5）The incidence of adverse reactions in the observation group was 4.44%（4/90）， which was significantly lower than that of 15.56%（14/90）in the control group，and the difference was statistically significant between the two groups （P＜0.05）. Conclusion LUO’s Nephropathy Recipe Ⅲ combined with conventional western medicine exerts satisfactory efficacy in treating stage 3-5 non-dialysis CKD patients with spleen-kidney deficiency with turbidity-toxin-stasis obstruction syndrome type，and the therapy can significantly alleviate the inflammatory response， improve the renal function， decrease the urinary protein excretion of the patients，with high safety profile.

R692

国家自然科学基金项目（编号：81973666）；广东省自然科学基金项目（编号：2019A1515010816）；广州市中医药特色诊疗技术 建设项目（穗卫中医【2022】7号）